Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
Making HIV medications free or low cost is very important for removing barriers to HIV care access, but it’s not enough to ensure adherence, Kevin Volpp […]
The emerging crisis of multidrug-resistant tuberculosis is a “personal and health system catastrophe” that’s occurring half a million times a year in the form of new […]
The U.S. National Institute of Allergy and Infectious Diseases will begin human testing of a vaccine candidate to prevent Ebola virus disease at the National Institutes […]
At the end of last May, Dr. William Fischer was immersed in his work as a physician, researcher, and instructor at the University of North Carolina […]